Bohui is the unusual case among Chinese plasma manufacturers: a company whose blood-products business sits alongside two unrelated divisions, one making in-vitro diagnostics and one making scientific instruments. Buyers regularly confuse the three and end up evaluating the wrong entity. This page separates them.
The entity, in verifiable terms
- Registered entity
- Beijing Bohui Innovation Biotechnology Group Co., Ltd. (北京博晖创新生物技术集团股份有限公司)
- Listing
- Shenzhen Stock Exchange, ticker 300318 — public filings available to any buyer who wants to read production and revenue figures directly
- Controlling group
- Junzheng Group, a private industrial group. Different from the state-owned platforms: group-level guarantees are less standard, so entity-level financials matter more in a tender
- Headquarters
- Beijing
- Plasma collection
- 23 single-donor plasma collection centres — the largest count of the three manufacturers on this site
- Production sites
- Four plasma-derived production bases. This matters for capacity questions: a manufacturer with one site has one point of failure
- Plasma portfolio
- 8 plasma products across 27 presentations, spanning albumin, immunoglobulin and coagulation factor classes
What is not part of this scope
Bohui's group structure includes an IVD division and a scientific-instrument division. Neither has anything to do with plasma export, and neither is offered through us. If you have received a Bohui quotation that references diagnostic reagents or laboratory equipment, it did not come from this channel.
A company that makes several things will be described online as if it makes one thing. Sort the entity from the division before you evaluate the supplier — the licence you need is issued to a site, not to a group.
The vaccine, and why it is on this page
Bohui manufactures a freeze-dried rabies vaccine using hamster kidney cells, licensed by NMPA under approval number S20000004, produced by Bohui Biopharmaceutical Co., Ltd. in Langfang, Hebei. The marketing licence holder and the manufacturing site are different legal entities — a distinction that matters when a tender asks who is responsible for the batch.
The other two manufacturers we carry do not offer this presentation. Baiyunshan makes a Vero-cell rabies vaccine instead; the cell substrate is a real difference, not a marketing one, and buyers with an existing registration dossier should check which substrate their approval references before switching.
What we supply from Bohui
Nine products — the broadest range from any single manufacturer on this site:
Human Albumin 20%
5 g / 25 ml and 10 g / 50 ml single-dose vials.
Human Immunoglobulin for Intravenous Injection (pH4)
pH4 process IVIG. The formulation difference affects tolerability profiles and is stated on the SPC, not inferred.
Human Immunoglobulin (IM)
Intramuscular presentation for passive immunisation.
Human Rabies Immunoglobulin
Passive immunisation for category III exposures.
Human Tetanus Immunoglobulin
Passive tetanus prophylaxis.
Human Hepatitis B Immunoglobulin
Passive immunisation for hepatitis B, including mother-to-child prophylaxis protocols.
Human Prothrombin Complex
Factors II, VII, IX and X.
Human Coagulation Factor VIII
Plasma-derived factor VIII for haemophilia A.
Rabies Vaccine (Hamster Kidney Cell)
Freeze-dried. NMPA S20000004. Manufactured at Langfang by Bohui Biopharmaceutical Co., Ltd.
See all seventeen products across three manufacturers →
How to verify any of this yourself
- Approval numbers. Each product page carries its NMPA number; this guide explains how to read the format and check it in the national database.
- Batch release. Plasma products and vaccines both require a release certificate from a designated national institute before they may be sold. The manufacturer cannot self-release. What that gate actually checks.
- The entity. Ticker 300318 in any public filing database will give you the audited picture, including which divisions contribute which revenue.
What this page does not claim
We are an authorised export partner, not the manufacturer. Availability, lead time, price and whether a presentation is currently in production are all subject to Bohui's confirmation. Nothing here is a claim about efficacy or safety, and nothing is directed at patients.